The FDA on January 27, 2012 approved INLYTA® for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. INLYTA® is a product of Pfizer, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement